<DOC>
	<DOC>NCT00723606</DOC>
	<brief_summary>This local registration study is to confirm the hypothesis of the efficacy, tolerability and safety of ziprasidone IM (intramuscular) in the Chinese population with agitation in schizophrenia</brief_summary>
	<brief_title>A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Male or female Chinese subjects aged 1865 years (including 65) at screening. Subjects meeting the ICD10 (Classification of Mental and Behavioral Disorders) criteria for schizophrenia (F20.X). Subjects who are in acute phase of schizophrenia and are appropriate to receive intramuscular medication for at least 3 days History of clinically significant physical illness especially myocardial infarction, non compensatory heart failure etc. Subjects receiving an investigational agent in the previous 3 months prior to screening. Use of antipsychotic agents within 12 hours or parenteral benzodiazepines within 4 hours prior to randomization and during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Intramuscular ziprasidone, agitation, efficacy and safety</keyword>
</DOC>